Aerie Pharmaceuticals Inc (AERI) 27.91 $AERI
Aerie Pharmaceuticals Is Speeding Towards Improving The Management Of Glaucoma
Prohost Biotech - Seeking Alpha - Thu Feb 12, 1:10PM CST
Aerie Pharmaceuticals (NASDAQ: AERI ) is a development-stage pharmaceutical Company focused on eye diseases, mainly glaucoma. The firm's lead product candidate, Rhopressa, is a once-daily triple-action eye drop that demonstrated ability to lower...
AERI: 27.91 (+0.14)
Recent Developments at Pharma Companies: Special Research on Aerie Pharmaceuticals, AEterna Zentaris, Affimed, Agenus, and Agile Therapeutics
PR Newswire - Tue Feb 03, 7:30AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Aerie Pharmaceuticals (NASDAQ: AERI), AEterna Zentaris (NASDAQ: AEZS), Affimed (NASDAQ: AFMD), Agenus (NASDAQ: AGEN), and Agile Therapeutics (NASDAQ: AGRX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AGEN: 5.03 (-0.01), AGRX: 8.57 (-0.41), AFMD: 5.70 (-0.25), AEZS: 0.53 (unch), AERI: 27.91 (+0.14)
Aerie Pharmaceuticals to Participate in Two Investor Conferences in February
Business Wire - Tue Feb 03, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that company management will present an overview of the company at the following conferences in February.
AERI: 27.91 (+0.14)
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
ITEK: (), NBS: 3.78 (+0.14), FOMX: 9.01 (-0.03), AERI: 27.91 (+0.14), OCUL: 31.25 (-0.01), AGN: 229.49 (+1.87), CANF: 3.85 (+0.05), ACAD: 34.21 (+0.37), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), OHRP: 7.38 (-0.30), CBMG: 24.32 (-1.17)
Commit To Buy Aerie Pharmaceuticals At $25, Earn 20.9% Annualized Using Options
at The Street - Tue Jan 13, 10:40AM CST
Investors considering a purchase of Aerie Pharmaceuticals Inc stock, but cautious about paying the going market price of $29.71/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
AERI: 27.91 (+0.14)
InsiderInsights.com Daily Round Up 1/12/15: BH, LTS, OPK, SNCR
InsiderInsights - at Seeking Alpha - Tue Jan 13, 9:51AM CST
AFAM: 30.88 (+0.37), RTN: 107.03 (-0.37), AERI: 27.91 (+0.14), MRD: 18.66 (+0.23), ADX: 14.08 (+0.11), LTS: 3.92 (-0.02), NNVC: 2.97 (-0.05), ARDX: 17.14 (+0.71), PANW: 135.27 (+2.26), CTRE: 13.46 (+0.26), PCTY: 28.59 (+0.38), BH: 416.41 (-1.55), WIW: 11.29 (unch), SNCR: 43.89 (+1.06), OPK: 13.80 (-0.28), UBA: 22.84 (-0.21), WIA: 11.49 (-0.03)
Aerie Pharma clinical trials ahead of schedule
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 7:30AM CST
AERI: 27.91 (+0.14)
Aerie Pharmaceuticals Announces Acceleration of Expected Timeline for Reporting Efficacy Results from Phase 3 Registration Trial ("Rocket 1"
of Rhopressa(TM)
Business Wire - Mon Jan 12, 5:30AM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today the acceleration of the expected timeline for reporting efficacy results from the Company's 400-patient Phase 3 registration trial ("Rocket 1" of Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Rocket 1 and a second Phase 3 registration trial ("Rocket 2" will measure efficacy over three months. The primary efficacy endpoint of the trials is to demonstrate non-inferiority of Rhopressa(TM) compared to timolol for the lowering of IOP. Timolol is the most widely used comparator in registration trials for lowering of IOP. In addition, there is a 12 month safety component to Rocket 2 and the Company is conducting a safety-only study in Canada, named "Rocket 3."
AERI: 27.91 (+0.14)
Ocular Hypertension - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/ftqgzh/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aerie Pharmaceuticals - Allergan - Amakem - Asahi Kasei Pharma - Bausch & Lomb - Can-Fite BioPharma - F. Hoffmann-La Roche - Inotek Pharmaceuticals - Kowa Company - Merck & Co - Ocular Therapeutix - Ono Pharmaceutical - Otsuka Holdings - Santen Pharmaceutical - Sylentis For more information visit http://www.researchandmarkets.com/research/ftqgzh/ocular
CANF: 3.85 (+0.05), AGN: 229.49 (+1.87), ITEK: (), MRK: 58.81 (-0.07), AERI: 27.91 (+0.14), OCUL: 31.25 (-0.01)
InsiderInsights.com Daily Round Up 12/30/14: XOMA, ECR, SNCR, AVK
InsiderInsights - at Seeking Alpha - Wed Dec 31, 10:49AM CST
BDSI: 14.92 (+0.93), ECR: 7.29 (+0.12), KFRC: 23.24 (+0.26), EVDY: 13.80 (-0.32), SAM: 303.26 (-0.97), AERI: 27.91 (+0.14), FUND: 7.47 (+0.05), RFMD: 16.59 (-0.35), AVK: 17.07 (-0.01), SNCR: 43.89 (+1.06), FTEK: 3.31 (+0.01), CAS: 6.14 (-0.01), COB: 10.25 (+0.18), XOMA: 3.41 (-0.01), CRM: 62.85 (+1.59)
Aerie: A Brilliant Future, Derisking In Progress, And The Making Of A Major Ophthalmic Pharmaceutical
Northern Fundamentals - at Seeking Alpha - Tue Dec 23, 11:45AM CST
AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), AERI: 27.91 (+0.14), NVS: 102.20 (-0.17)
Aerie Pharmaceuticals Added to NASDAQ Biotechnology Index (NBI)
Business Wire - Tue Dec 16, 5:30AM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that it has been selected for addition to the NASDAQ Biotechnology Index(R) (NASDAQ:^NBI), which will become effective upon market open on Monday, December 22, 2014.
IBB: 323.46 (+3.04), AERI: 27.91 (+0.14)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Spin Doctors; Data And Market Projections From Aerie Pharmaceuticals, Inc. Are Too Optimistic
Sirius Capital - Seeking Alpha - Fri Dec 12, 7:00AM CST
During the Cold War era there was a famous joke about a race between a US and a USSR runner in which the American crossed the finish line first. The headline in the Communist party newspaper 'Pravda' had read 'In an international race, the Soviet...
AERI: 27.91 (+0.14)
Aerie Pharma completes enrollment in Rhopressa Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 7:47AM CST
AERI: 27.91 (+0.14)
Aerie Pharmaceuticals Completes Enrollment in Phase 3 Registration Trial ("Rocket 1" of Rhopressa(TM), Novel Triple-Action Product to Lower Intraocular Pressure in Patients with Glaucoma
Business Wire - Tue Dec 02, 5:30AM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today the completion of enrollment in the Company's 400-patient Phase 3 registration trial ("Rocket 1" of Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Rocket 1 and a second Phase 3 registration trial ("Rocket 2" will measure efficacy over three months. The primary efficacy endpoint of the trials is to demonstrate non-inferiority of IOP lowering for Rhopressa(TM) compared to timolol. Timolol is the most widely used comparator in registration trials for glaucoma. In addition, the Company is conducting a safety-only study in Canada, named "Rocket 3."
AERI: 27.91 (+0.14)
Aerie Pharmaceuticals to Present at the Piper Jaffray 26th Annual Healthcare Conference
Business Wire - Mon Nov 24, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Richard Rubino, chief financial officer, will present in a fireside chat discussion at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014 at 11:30 a.m. Eastern Time in New York, NY. Mr. Rubino will provide an Aerie overview and business update.
AERI: 27.91 (+0.14)
Aerie Pharmaceuticals to Present at the 2014 Stifel Nicolaus Annual Healthcare Conference
Business Wire - Wed Nov 12, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., chairman and chief executive officer will present at the 2014 Stifel Nicolaus Annual Healthcare Conference on Tuesday, November 18, 2014 at 8:35 a.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.
AERI: 27.91 (+0.14)
Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 8:40PM CST
AERI: 27.91 (+0.14)
Aerie Pharmaceuticals Is Speeding Towards Improving The Management Of Glaucoma
Prohost Biotech - Seeking Alpha - Thu Feb 12, 1:10PM CST
Aerie Pharmaceuticals (NASDAQ: AERI ) is a development-stage pharmaceutical Company focused on eye diseases, mainly glaucoma. The firm's lead product candidate, Rhopressa, is a once-daily triple-action eye drop that demonstrated ability to lower...
AERI: 27.91 (+0.14)
Recent Developments at Pharma Companies: Special Research on Aerie Pharmaceuticals, AEterna Zentaris, Affimed, Agenus, and Agile Therapeutics
PR Newswire - Tue Feb 03, 7:30AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Aerie Pharmaceuticals (NASDAQ: AERI), AEterna Zentaris (NASDAQ: AEZS), Affimed (NASDAQ: AFMD), Agenus (NASDAQ: AGEN), and Agile Therapeutics (NASDAQ: AGRX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AGEN: 5.03 (-0.01), AGRX: 8.57 (-0.41), AFMD: 5.70 (-0.25), AEZS: 0.53 (unch), AERI: 27.91 (+0.14)
Aerie Pharmaceuticals to Participate in Two Investor Conferences in February
Business Wire - Tue Feb 03, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that company management will present an overview of the company at the following conferences in February.
AERI: 27.91 (+0.14)
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
ITEK: (), NBS: 3.78 (+0.14), FOMX: 9.01 (-0.03), AERI: 27.91 (+0.14), OCUL: 31.25 (-0.01), AGN: 229.49 (+1.87), CANF: 3.85 (+0.05), ACAD: 34.21 (+0.37), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), OHRP: 7.38 (-0.30), CBMG: 24.32 (-1.17)
Commit To Buy Aerie Pharmaceuticals At $25, Earn 20.9% Annualized Using Options
at The Street - Tue Jan 13, 10:40AM CST
Investors considering a purchase of Aerie Pharmaceuticals Inc stock, but cautious about paying the going market price of $29.71/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
AERI: 27.91 (+0.14)
InsiderInsights.com Daily Round Up 1/12/15: BH, LTS, OPK, SNCR
InsiderInsights - at Seeking Alpha - Tue Jan 13, 9:51AM CST
AFAM: 30.88 (+0.37), RTN: 107.03 (-0.37), AERI: 27.91 (+0.14), MRD: 18.66 (+0.23), ADX: 14.08 (+0.11), LTS: 3.92 (-0.02), NNVC: 2.97 (-0.05), ARDX: 17.14 (+0.71), PANW: 135.27 (+2.26), CTRE: 13.46 (+0.26), PCTY: 28.59 (+0.38), BH: 416.41 (-1.55), WIW: 11.29 (unch), SNCR: 43.89 (+1.06), OPK: 13.80 (-0.28), UBA: 22.84 (-0.21), WIA: 11.49 (-0.03)
Aerie Pharma clinical trials ahead of schedule
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 7:30AM CST
AERI: 27.91 (+0.14)
Aerie Pharmaceuticals Announces Acceleration of Expected Timeline for Reporting Efficacy Results from Phase 3 Registration Trial ("Rocket 1"
of Rhopressa(TM) Business Wire - Mon Jan 12, 5:30AM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today the acceleration of the expected timeline for reporting efficacy results from the Company's 400-patient Phase 3 registration trial ("Rocket 1"
of Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Rocket 1 and a second Phase 3 registration trial ("Rocket 2" will measure efficacy over three months. The primary efficacy endpoint of the trials is to demonstrate non-inferiority of Rhopressa(TM) compared to timolol for the lowering of IOP. Timolol is the most widely used comparator in registration trials for lowering of IOP. In addition, there is a 12 month safety component to Rocket 2 and the Company is conducting a safety-only study in Canada, named "Rocket 3." AERI: 27.91 (+0.14)
Ocular Hypertension - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/ftqgzh/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aerie Pharmaceuticals - Allergan - Amakem - Asahi Kasei Pharma - Bausch & Lomb - Can-Fite BioPharma - F. Hoffmann-La Roche - Inotek Pharmaceuticals - Kowa Company - Merck & Co - Ocular Therapeutix - Ono Pharmaceutical - Otsuka Holdings - Santen Pharmaceutical - Sylentis For more information visit http://www.researchandmarkets.com/research/ftqgzh/ocular
CANF: 3.85 (+0.05), AGN: 229.49 (+1.87), ITEK: (), MRK: 58.81 (-0.07), AERI: 27.91 (+0.14), OCUL: 31.25 (-0.01)
InsiderInsights.com Daily Round Up 12/30/14: XOMA, ECR, SNCR, AVK
InsiderInsights - at Seeking Alpha - Wed Dec 31, 10:49AM CST
BDSI: 14.92 (+0.93), ECR: 7.29 (+0.12), KFRC: 23.24 (+0.26), EVDY: 13.80 (-0.32), SAM: 303.26 (-0.97), AERI: 27.91 (+0.14), FUND: 7.47 (+0.05), RFMD: 16.59 (-0.35), AVK: 17.07 (-0.01), SNCR: 43.89 (+1.06), FTEK: 3.31 (+0.01), CAS: 6.14 (-0.01), COB: 10.25 (+0.18), XOMA: 3.41 (-0.01), CRM: 62.85 (+1.59)
Aerie: A Brilliant Future, Derisking In Progress, And The Making Of A Major Ophthalmic Pharmaceutical
Northern Fundamentals - at Seeking Alpha - Tue Dec 23, 11:45AM CST
AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), AERI: 27.91 (+0.14), NVS: 102.20 (-0.17)
Aerie Pharmaceuticals Added to NASDAQ Biotechnology Index (NBI)
Business Wire - Tue Dec 16, 5:30AM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that it has been selected for addition to the NASDAQ Biotechnology Index(R) (NASDAQ:^NBI), which will become effective upon market open on Monday, December 22, 2014.
IBB: 323.46 (+3.04), AERI: 27.91 (+0.14)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Spin Doctors; Data And Market Projections From Aerie Pharmaceuticals, Inc. Are Too Optimistic
Sirius Capital - Seeking Alpha - Fri Dec 12, 7:00AM CST
During the Cold War era there was a famous joke about a race between a US and a USSR runner in which the American crossed the finish line first. The headline in the Communist party newspaper 'Pravda' had read 'In an international race, the Soviet...
AERI: 27.91 (+0.14)
Aerie Pharma completes enrollment in Rhopressa Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 7:47AM CST
AERI: 27.91 (+0.14)
Aerie Pharmaceuticals Completes Enrollment in Phase 3 Registration Trial ("Rocket 1"
of Rhopressa(TM), Novel Triple-Action Product to Lower Intraocular Pressure in Patients with Glaucoma Business Wire - Tue Dec 02, 5:30AM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today the completion of enrollment in the Company's 400-patient Phase 3 registration trial ("Rocket 1"
of Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Rocket 1 and a second Phase 3 registration trial ("Rocket 2" will measure efficacy over three months. The primary efficacy endpoint of the trials is to demonstrate non-inferiority of IOP lowering for Rhopressa(TM) compared to timolol. Timolol is the most widely used comparator in registration trials for glaucoma. In addition, the Company is conducting a safety-only study in Canada, named "Rocket 3." AERI: 27.91 (+0.14)
Aerie Pharmaceuticals to Present at the Piper Jaffray 26th Annual Healthcare Conference
Business Wire - Mon Nov 24, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Richard Rubino, chief financial officer, will present in a fireside chat discussion at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014 at 11:30 a.m. Eastern Time in New York, NY. Mr. Rubino will provide an Aerie overview and business update.
AERI: 27.91 (+0.14)
Aerie Pharmaceuticals to Present at the 2014 Stifel Nicolaus Annual Healthcare Conference
Business Wire - Wed Nov 12, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., chairman and chief executive officer will present at the 2014 Stifel Nicolaus Annual Healthcare Conference on Tuesday, November 18, 2014 at 8:35 a.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.
AERI: 27.91 (+0.14)
Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 8:40PM CST
AERI: 27.91 (+0.14)
